MLTX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
79.9M
+29.5%
61.7M
-11.9%
70.0M
+7.4%
65.2M
-8.7%
71.4M
R&D
68.9M
+37.1%
50.2M
-7.9%
54.5M
-2.7%
56.0M
-7.6%
60.6M
SG&A
11.0M
-4.0%
11.4M
-26.2%
15.5M
+68.4%
9.2M
-14.7%
10.8M
Operating Income
-79852000
-29.5%
-61660000
+11.9%
-70024000
-7.4%
-65218000
+8.7%
-71434000
EBITDA
-78947000
-29.9%
-60764000
+12.2%
-69179000
-7.3%
-64467000
+8.8%
-70689000
Net Income
-79545000
-28.7%
-61805000
+11.3%
-69707000
-10.6%
-63018000
+10.9%
-70694000
EPS (Basic)
$-0.93
-10.7%
$-0.84
+14.3%
$-0.98
-11.4%
$-0.88
+20.0%
$-1.10
EPS (Diluted)
$-0.93
-10.7%
$-0.84
+14.3%
$-0.98
-11.4%
$-0.88
+20.0%
$-1.10
Shares (Diluted)
85.4M
+15.5%
73.9M
+3.7%
71.3M
+4.9%
68.0M
+7.3%
63.4M
MoonLake Immunotherapeutics (MLTX) — Financials